<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04115826</url>
  </required_header>
  <id_info>
    <org_study_id>19-0402</org_study_id>
    <nct_id>NCT04115826</nct_id>
  </id_info>
  <brief_title>ESWL vs. Pancreatoscopy-guided Lithotripsy for Painful Chronic Calcific Pancreatitis</brief_title>
  <official_title>Per-oral Pancreatoscopy-guided Lithotripsy vs. Extracorporeal Shock Wave Lithotripsy in Chronic Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center randomized controlled trial comparing extracorporeal shock-wave
      lithotripsy (ESWL) with per-oral pancreatoscopy-guided lithotripsy (PPL) in the treatment of
      patients with chronic pancreatitis and refractory main pancreatic duct stones. This study
      will be comparing the two treatment options for patients who have stones that fail initial
      endoscopic therapy via endoscopic retrograde pancreatography (ERCP). The study will look at
      the stone clearance rates and patient-centered outcomes including quality of life and pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic pancreatitis frequently develop obstructing pancreatic duct stones
      which can lead to severe pain. Current standard methods to remove these stones include ERCP
      and extracorporeal shock-wave lithotripsy (ESWL) which are limited in removing larger and
      multiple impacted stones. Availability in the USA of ESWL for this indication also may be
      limited even at major referral centers. The introduction of single-operator per-oral
      pancreatoscopy (SpyGlassTM) has enabled direct intraductal visualization to target stones.
      Retrospective studies demonstrate a high success rate but literature is quite limited,
      uncontrolled, and highly selective. Further, many experts and recent European Society
      Guidelines suggest that ESWL is the only primary therapy for larger stones (5mm or larger)
      and that intraductal endoscopy and lithotripsy should only be used for 'salvage' therapy in
      select patients.

      A critical need exists to compare the efficacy of per oral pancreatoscopy-guided lithotripsy
      (PPL) with ESWL to determine which therapy is most efficacious in removing refractory PD
      stones. The investigators believe ERCP with POP has distinct advantages of localizing
      'shocks' to the stones, helping to identify and treat underlying strictures in the duct, and
      lithotripsy of multiple stones can be performed at a single session with a recent
      multi-center international retrospective study showing all stones removed in a single session
      in over 70% of cases. Therefore, this project seeks to change the perceived standard of care
      as it relates to symptomatic pancreatic duct stones in this population, shifting the pendulum
      towards endoscopic and specifically pancreatoscopy-guided therapy.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 2, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The investigator interpreting final stone clearance pancreatograms will be blinded to the intervention received.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Stone Clearance Rate</measure>
    <time_frame>Up to 4 hours (four 1-hour sessions)</time_frame>
    <description>The rate of complete clearance of the main pancreatic duct of all stones.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change In Quality of Life as Measured Using PANQOLI Score</measure>
    <time_frame>At the conclusion of treatment success/failure at 1,3,6, and 12 months follow-up</time_frame>
    <description>Change in quality of life as measured using the PANQOLI (PANcreatitis Quality of Life Instrument), a chronic pancreatitis-specific quality of life instrument. This instrument has a score range from 0 to 100, which higher scores denoting better quality of life. The questionnaire has 18 items and questions 1, 2, 3, 4, 5, 6, 12, 13, 14, 15, 16, 17, and 18 are reverse scored while items 7, 8, 9, 10, and 11 are scored at face value. The final score is the sum of the scores from all 18 questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Levels as Measured Using the COMPAT Score</measure>
    <time_frame>At the conclusion of treatment success/failure at 1,3,6, and 12 months follow-up</time_frame>
    <description>Change in pain levels as measured using the comprehensive pain assessment tool, (COMPAT), a chronic pancreatitis-specific pain questionnaire. The questionnaire consists of 23 questions. A score is assessed for question # 14, which consists of 28 questions with scores ranging from 0 to 10, with 10 representing worse pain. A maximum score of 280 is possible for this component of the COMPAT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pancreatitis, Chronic</condition>
  <arm_group>
    <arm_group_label>Extracorporeal Shock-Wave Lithotripsy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Stone localization will first be performed by obtaining high-quality plain films of the pancreatic area in left and right oblique positions using a two-dimensional radiologic targeting system.Depending on the stone localization, ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Per-oral Pancreatoscopy-guided Lithotripsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard ERP will be performed to cannulate the PD, perform pancreatic sphincterotomy, and stricture dilation as necessary. A pancreatoscope (Spyglass Digital System, Boston Scientific, Marlborough, MA) will then be inserted through the duodenoscope into the PD. For PPL, electrical pulses will be delivered through an aqueous medium by EHL or LL with the probe tip in contact with or 1-2mm away from the stone. Settings for EHL (1.9F fiber; Autolith, Northgate Technologies, Elgin, IL) are 10-20 pulses/second with a power of 50-100; and for LL (200, 272, or 365 micrometer fiber, Versa Pulse Power Suite 20-W Holmium laser, New Star, Roseville, CA) ranging from 0.8 - 2.5 Joules with a frequency of 8-15Hz and power of 9-30 W. A maximum of 1 hour of intraductal lithotripsy will be allowed to reduce performance bias.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Per-oral Pancreatoscopy-guided Lithotripsy</intervention_name>
    <description>Per-oral Pancreatoscopy-guided lithotripsy will be administered for a maximum of 4 sessions (1 hour max per session). Either electrohydraulic lithotripsy or laser lithotripsy will be allowed during the session at the discretion of the endoscopist.</description>
    <arm_group_label>Per-oral Pancreatoscopy-guided Lithotripsy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extracorporeal Shock-Wave Lithotripsy</intervention_name>
    <description>ESWL will then be performed with the patient in either slight left or right lateral decubitus with shock waves entering the body from the ventral side. The shockwaves will be focused first on the most distally located stone within the main duct and then on other calculi moving from the head towards the body. If a stent has been inserted during preceding ERP then this may also serve as a guide to target main pancreatic duct stones by ESWL. A total of one hour of ESWL at a rate of 60-120 shocks/minute will be delivered in one treatment session.</description>
    <arm_group_label>Extracorporeal Shock-Wave Lithotripsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with abdominal pain secondary to chronic calcific pancreatitis and main
             pancreatic duct stones found on cross-sectional imaging, EUS, or ERP.

          -  Subjects aged 18-80.

          -  Subjects must have failed at least one prior attempt of standard ERP to remove the PD
             stones.

          -  Main PD stones in the head or body that are greater than 50% of the immediate
             downstream diameter of the pancreatic duct.

          -  Stones â‰¥5 mm in diameter or impacted in the main PD on cross-sectional imaging or EUS.
             If multiple locations of stones are noted within the main PD, pancreatic tail stones
             cannot comprise more than one-third of the stone burden within the main PD.

        Exclusion Criteria:

          -  Subjects who have previously received PPL or ESWL.

          -  Patients with PD stones isolated in the tail or side branches of the main duct.

          -  Inability to place a transpapillary pancreatic duct stent at index ERP.

          -  Patients with prior pancreatic surgery

          -  Pancreas divisum or acquired pancreas divisum requiring minor papilla cannulation

          -  Pregnancy

          -  Significant cardiopulmonary co-morbidities precluding general anesthesia

          -  Patients with implanted cardiac pacemakers or defibrillators

          -  Patients with coagulation disorders that cannot be corrected to an INR below 2.0
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raj J Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado - Anschutz Medical Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic duct stone</keyword>
  <keyword>extracorporeal shock-wave lithotripsy</keyword>
  <keyword>pancreatoscopy</keyword>
  <keyword>quality of life</keyword>
  <keyword>chronic pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified data will be available to researchers</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The data will become available at the conclusion of the study once the results are published.</ipd_time_frame>
    <ipd_access_criteria>Formal proposal required</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/26/NCT04115826/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

